ES2138085T3 - Xinafoato de salmeterol con tamaño de particula controlado. - Google Patents

Xinafoato de salmeterol con tamaño de particula controlado.

Info

Publication number
ES2138085T3
ES2138085T3 ES94918982T ES94918982T ES2138085T3 ES 2138085 T3 ES2138085 T3 ES 2138085T3 ES 94918982 T ES94918982 T ES 94918982T ES 94918982 T ES94918982 T ES 94918982T ES 2138085 T3 ES2138085 T3 ES 2138085T3
Authority
ES
Spain
Prior art keywords
pct
particle size
salmeterol xinafoate
controlled particle
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94918982T
Other languages
English (en)
Inventor
Peter York
Mazen Hanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2138085T3 publication Critical patent/ES2138085T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Investigating Or Analyzing Materials By The Use Of Fluid Adsorption Or Reactions (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

LA INVENCION SE REFIERE A PRODUCTOS EN PARTICULAS QUE SE PUEDEN PREPARAR MEDIANTE METODOS Y APARATOS QUE HACEN USO DE FLUIDOS SUPERCRITICOS. DE MODO MAS PARTICULAR, LA INVENCION SE REFIERE A PRODUCTOS FARMACEUTICOS, EN PARTICULAR FORMAS CRISTALINAS FACILMENTE MANIPULADAS Y FACILMENTE FLUIDIFICADAS DE XINAFOATO DE SALMETEROL, CON UN TAMAÑO Y FORMA DE LAS PARTICULAS CONTROLADOS.
ES94918982T 1993-07-01 1994-06-30 Xinafoato de salmeterol con tamaño de particula controlado. Expired - Lifetime ES2138085T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939313650A GB9313650D0 (en) 1993-07-01 1993-07-01 Method and apparatus for the formation of particles

Publications (1)

Publication Number Publication Date
ES2138085T3 true ES2138085T3 (es) 2000-01-01

Family

ID=10738146

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94918982T Expired - Lifetime ES2138085T3 (es) 1993-07-01 1994-06-30 Xinafoato de salmeterol con tamaño de particula controlado.

Country Status (20)

Country Link
US (1) US5795594A (es)
EP (1) EP0706507B1 (es)
JP (1) JP3839042B2 (es)
CN (1) CN1062854C (es)
AT (1) ATE184870T1 (es)
AU (1) AU684795B2 (es)
BR (1) BR9406995A (es)
CA (1) CA2165830C (es)
DE (1) DE69420844T2 (es)
DK (1) DK0706507T3 (es)
ES (1) ES2138085T3 (es)
FI (1) FI956343A (es)
GB (1) GB9313650D0 (es)
GR (1) GR3032065T3 (es)
HK (1) HK1004216A1 (es)
HU (1) HUT73733A (es)
NO (1) NO304940B1 (es)
NZ (1) NZ267696A (es)
RU (1) RU2136655C1 (es)
WO (1) WO1995001324A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE386506T1 (de) * 1995-10-17 2008-03-15 Jagotec Ag Verabreichung unlöslicher arzneistoffe
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9806462D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB9810559D0 (en) * 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
SE9804001D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New process
EP1185248B1 (en) * 1999-06-09 2012-05-02 Robert E. Sievers Supercritical fluid-assisted nebulization and bubble drying
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB9915975D0 (en) * 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
CA2382821A1 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
FR2798290B1 (fr) * 1999-09-11 2003-09-12 Glaxo Group Ltd Formulation pharmaceutique de propionate de fluticasone
FR2803538B1 (fr) * 1999-12-15 2002-06-07 Separex Sa Procede et dispositif de captage de fines particules par percolation dans un lit de granules
US6761909B1 (en) 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
WO2001045731A1 (en) * 1999-12-21 2001-06-28 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US6756062B2 (en) 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US8551526B2 (en) * 2000-11-03 2013-10-08 Board Of Regents, The University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
KR100858956B1 (ko) 2001-02-26 2008-09-17 돔페 파르마 에스.피.에이. 미세 및 초미세 입자를 형성하기 위한 장치 및 방법
US7332111B2 (en) * 2001-07-10 2008-02-19 The Regents Of The University Of Colorado Devices and methods for the production of particles
GB0117403D0 (en) * 2001-07-17 2001-09-05 Pharmacia & Upjohn Spa Solvent-free crystalline anthracycline derivatives
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
JP2005511521A (ja) * 2001-10-10 2005-04-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 加圧ガス状流体による粉末処理
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
ES2415654T3 (es) * 2001-11-20 2013-07-26 Civitas Therapeutics, Inc. Composiciones particuladas mejoradas para suministro pulmonar
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
JP2005520847A (ja) * 2002-03-20 2005-07-14 アドバンスト インハレーション リサーチ，インコーポレイテッド 肺投与用ｈＧＨ（ヒト成長ホルモン）製剤
WO2003090715A2 (en) * 2002-04-25 2003-11-06 Nektar Therapeutics Uk Ltd Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
WO2004056342A1 (en) * 2002-12-19 2004-07-08 Baxter International, Inc. Process for preparing combination pharmaceutical formulations using supercritical fluids
DE10351663A1 (de) * 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
KR20050088243A (ko) * 2002-12-30 2005-09-02 넥타르 테라퓨틱스 프리필름화 분무기
US6915966B2 (en) * 2003-01-29 2005-07-12 Specialty Minerals (Michigan) Inc. Apparatus for the gunning of a refractory material and nozzles for same
MY147403A (en) * 2003-04-29 2012-11-30 Kowa Co Composition containing medicine extremely slightly solube in water and method for preparation thereof
CA2524773C (en) 2003-05-08 2014-04-08 Nektar Therapeutics Uk Ltd Particulate coformulations of active substances with excipients
JP4206317B2 (ja) * 2003-09-10 2009-01-07 花王株式会社 有機板状粒子の製造方法
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
WO2006040598A2 (en) * 2004-10-12 2006-04-20 Generics (Uk) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US7854397B2 (en) * 2005-01-21 2010-12-21 Specialty Minerals (Michigan) Inc. Long throw shotcrete nozzle
WO2007009164A1 (en) 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
CN1973812B (zh) * 2006-11-03 2010-12-08 谭登平 一种将超临界二氧化碳萃取物固体粉末化的方法
WO2008097664A1 (en) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
EP2127641A1 (en) * 2008-05-26 2009-12-02 Inke, S.A. Micronisable form of salmeterol xinafoate
WO2012032546A2 (en) 2010-09-08 2012-03-15 Cadila Healthcare Limited Process for the preparation of salmeterol and its intermediates
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
US9908062B2 (en) 2012-11-20 2018-03-06 Andrew Paul Joseph Extraction apparatus and method
US9132363B2 (en) 2012-11-20 2015-09-15 Apeks Llc Extraction system
JP2021141003A (ja) * 2020-03-07 2021-09-16 エムテックスマート株式会社 ２次電池の製造方法または２次電池
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
EP0616525B1 (en) * 1991-12-12 1995-09-27 Glaxo Group Limited Pharmaceutical aerosol formulation
US5509404A (en) * 1994-07-11 1996-04-23 Aradigm Corporation Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values

Also Published As

Publication number Publication date
CA2165830A1 (en) 1995-01-12
FI956343A0 (fi) 1995-12-29
DE69420844T2 (de) 2000-03-16
RU2136655C1 (ru) 1999-09-10
WO1995001324A1 (en) 1995-01-12
CN1062854C (zh) 2001-03-07
ATE184870T1 (de) 1999-10-15
GB9313650D0 (en) 1993-08-18
HUT73733A (en) 1996-09-30
DK0706507T3 (da) 2000-04-10
AU7007094A (en) 1995-01-24
CA2165830C (en) 2005-04-26
EP0706507A1 (en) 1996-04-17
JPH08512047A (ja) 1996-12-17
JP3839042B2 (ja) 2006-11-01
DE69420844D1 (de) 1999-10-28
US5795594A (en) 1998-08-18
HK1004216A1 (en) 1998-11-20
NO304940B1 (no) 1999-03-08
FI956343A (fi) 1996-02-15
NZ267696A (en) 1997-11-24
GR3032065T3 (en) 2000-03-31
EP0706507B1 (en) 1999-09-22
CN1129932A (zh) 1996-08-28
NO955355D0 (no) 1995-12-29
NO955355L (no) 1996-02-29
AU684795B2 (en) 1998-01-08
HU9503772D0 (en) 1996-02-28
BR9406995A (pt) 1996-09-10

Similar Documents

Publication Publication Date Title
ES2138085T3 (es) Xinafoato de salmeterol con tamaño de particula controlado.
EP0766514A4 (en) DISCHARGE DEVICE FOR SHOULDER SHOOTING
IL105541A0 (en) Monoclonal antibodies to gp130 protein,processes for the preparation thereof and pharmaceutical compositions containing the same
AR012717A1 (es) Trihidrato de la sal de magnesio de s-omeprazol, proceso para su preparacion, composicion farmaceutica, y uso de dicho trihidrato para la fabricacion de medicamentos.
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
ITMO920035A0 (it) Flacone contagocce particolarmente per prodotti farmaceutici attivabili all'uso per miscelare
ZA976967B (en) Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the of said device.
DK0706380T3 (da) Indkapslet farmaceutisk præparat
ZA928585B (en) Process for agglomerating particulate material and products made from such processes.
DE69327812D1 (de) Arsen-enthaltende arzneimittel zur behandlung des chronischen ermüdungssyndroms
HU9401412D0 (en) Process for producing dry- processed particles, the produced dry-processed paricles, and pharmaceutical compositions containing them
IT1239447B (it) Sistema e dispositivi per la preparazione di prodotti di ricupero da rifiuti e simili in particolare di ammendante agricolo arricchito.
DK0654028T3 (da) 3- og 5-substituerede 1,2,3,4-oxatriazol-5-iminforbindelser og fremgangsmåde til fremstilling deraf, farmaceutisk præparat indeholdende disse forbindelser samt forbindelsernes anvendelse til fremstilling af lægemidler
AU1269195A (en) Rearrangement device for container with loose articles and/or products, and rearrangement method
IT1239273B (it) Procedimento di preparazione di aromi naturali al tartufo e prodotti ottenuti.
FR2702929B1 (fr) Microparticules de type matriciel renfermant au moins un agent biocide, procédé pour leur préparation et produits manufacturés en contenant.
IT1228902B (it) Procedimento ed impianto per la preparazione di prodotti farmaceutici in genere.
TH14468A (th) " วิธีการดำเนินกรรมวิธีกับมวลชีวภาพประเภทลิกโนเซลลูโลส "
ITBO930419A0 (it) Gruppo per il rilevamento del peso di prodotti, in particolare prodot-ti farmaceutici.
DE60210268D1 (de) Verfahren zur herstellung von 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one, dessen 17-ester und pharmazeutische zubereitungen die sie enthalten
IT1282561B1 (it) Valvola per il trattamento di prodotti in pezzi fragili o in polvere.
IT1320832B1 (it) Procedimento e impianto per il trattamento di prodotti di uovo esimili, destinati all'uso alimentare.
ITBO930163A1 (it) Dispositivo particolarmente adatto per il dosaggio di prodotti delicati di natura granulare e/o polverulenti e sufficientemente fluidi
TH48734EX (th) ขวด
TH14468EX (th) " วิธีการดำเนินกรรมวิธีกับมวลชีวภาพประเภทลิกโนเซลลูโลส "

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 706507

Country of ref document: ES